MA54657A - Compositions pour augmenter la demi-vie d'un agent thérapeutique chez les chiens et procédés d'utilisation - Google Patents

Compositions pour augmenter la demi-vie d'un agent thérapeutique chez les chiens et procédés d'utilisation

Info

Publication number
MA54657A
MA54657A MA054657A MA54657A MA54657A MA 54657 A MA54657 A MA 54657A MA 054657 A MA054657 A MA 054657A MA 54657 A MA54657 A MA 54657A MA 54657 A MA54657 A MA 54657A
Authority
MA
Morocco
Prior art keywords
dogs
compositions
life
increasing
methods
Prior art date
Application number
MA054657A
Other languages
English (en)
Inventor
William Brondyk
Brett Chevalier
Juergen Horn
Madhusudan Natarajan
Original Assignee
Invetx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Invetx Inc filed Critical Invetx Inc
Publication of MA54657A publication Critical patent/MA54657A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA054657A 2019-01-03 2020-01-02 Compositions pour augmenter la demi-vie d'un agent thérapeutique chez les chiens et procédés d'utilisation MA54657A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962788035P 2019-01-03 2019-01-03

Publications (1)

Publication Number Publication Date
MA54657A true MA54657A (fr) 2021-11-10

Family

ID=69740520

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054657A MA54657A (fr) 2019-01-03 2020-01-02 Compositions pour augmenter la demi-vie d'un agent thérapeutique chez les chiens et procédés d'utilisation

Country Status (9)

Country Link
US (7) US11542333B2 (fr)
EP (1) EP3906259A2 (fr)
CN (2) CN113544153B (fr)
AU (1) AU2020205073A1 (fr)
BR (1) BR112021012513A2 (fr)
MA (1) MA54657A (fr)
MX (1) MX2021008144A (fr)
SG (1) SG11202106478UA (fr)
WO (1) WO2020142625A2 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
CA3071337A1 (fr) 2017-08-15 2019-02-21 Kindred Biosciences, Inc. Variants d'igg fc a usage veterinaire
CN113227134A (zh) * 2018-12-05 2021-08-06 株式会社梅花治疗 抗体的Fc区变体
SG11202106478UA (en) 2019-01-03 2021-07-29 Invetx Inc Compositions for increasing half-life of a therapeutic agent in canines and methods of use
US20230348577A1 (en) 2020-02-19 2023-11-02 Adivo Gmbh Modified fc regions
BR112022020944A2 (pt) * 2020-04-17 2022-12-27 Zoetis Services Llc Variantes de anticorpos caninos
BR112022021216A2 (pt) * 2020-04-22 2022-12-06 Kindred Biosciences Inc Anticorpos, ácido nucleico, célula hospedeira, composições farmacêuticas, métodos de produção de um anticorpo e de tratamento de uma espécie de animal de companhia e métodos para reduzir a função de sinalização de il31 em uma célula e para detectar il31 em uma amostra
GB202005879D0 (en) * 2020-04-22 2020-06-03 Petmedix Ltd Heterodimeric proteins
KR20230034954A (ko) 2020-05-11 2023-03-10 인베티엑스 인코포레이티드 개에서 치료제의 반감기를 증가시키기 위한 조성물 및 사용 방법
WO2021251438A1 (fr) * 2020-06-10 2021-12-16 株式会社バイカ・セラピュティクス Protéine de fusion contenant un polypeptide d'érythropoïétine
CN119899259A (zh) * 2020-07-10 2025-04-29 因外泰克斯公司 用于延长治疗剂在猫科动物中的半衰期的组合物和使用方法
EP4217384A2 (fr) * 2020-09-28 2023-08-02 Zoetis Services LLC Variants d'anticorps canin
US12103961B2 (en) 2020-12-07 2024-10-01 Invetx, Inc. Compositions for increasing half-life of a therapeutic agent in livestock animals and methods of use
CA3207285A1 (fr) * 2021-01-28 2022-08-04 Zoetis Services Llc Mutations dans des regions constantes d'anticorps canins
CA3228830A1 (fr) * 2021-08-06 2023-02-09 Petmedix Ltd Variants de fc d'anticorps
WO2023021169A1 (fr) 2021-08-20 2023-02-23 Intervet International B.V. Anticorps et protéines de fusion igg présentant une demi-vie accrue
WO2023067358A1 (fr) 2021-10-21 2023-04-27 Petmedix Ltd Protéines comprenant le domaine extracellulaire de p75ntr
US11608371B1 (en) * 2021-10-21 2023-03-21 Petmedix Ltd Therapeutic molecules
JP2024546759A (ja) * 2021-12-16 2024-12-26 インターベット インターナショナル ベー． フェー． イヌインターロイキン－３１受容体アルファｉｉに対するイヌ化抗体
KR20250122509A (ko) * 2022-12-16 2025-08-13 벳맙 바이오사이언스 인코포레이티드 항-IL23 및 항-TNFα 항체: 조성물 및 수의학적 용도
AU2023417626A1 (en) 2022-12-27 2025-07-10 Invetx, Inc. Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use
WO2024155982A2 (fr) 2023-01-20 2024-07-25 Invetx, Inc. Agents de liaison bispécifiques destinés à être utilisés sur des animaux de compagnie
EP4652197A1 (fr) 2023-01-20 2025-11-26 Petmedix Ltd. Anticorps thérapeutiques
KR20250141832A (ko) 2023-02-09 2025-09-29 펫메딕스 리미티드 P75 뉴로트로핀 수용체(p75ntr)의 세포외 도메인 변이체를 포함하는 치료 분자
EP4665756A1 (fr) * 2023-02-13 2025-12-24 Intervet International B.V. Anticorps canins dirigés contre l'il-4 canine
CN121002060A (zh) * 2023-02-13 2025-11-21 英特维特国际股份有限公司 犬il-13的犬抗体

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
JP3126980B2 (ja) 1991-03-11 2001-01-22 ザ・ユニバーシテイ・オブ・ジヨージア・リサーチ・フアウンデーシヨン・インコーポレーテツド レニラ（ｒｅｎｉｌｌａ）ルシフェラーゼのクローニング及び発現
AU694745B2 (en) 1993-09-10 1998-07-30 Trustees Of Columbia University In The City Of New York, The Uses of green fluorescent protein
WO1995021191A1 (fr) 1994-02-04 1995-08-10 William Ward Indicateur bioluminescent fonde sur l'expression d'un gene codant pour une proteine modifiee a fluorescence verte
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
US5925558A (en) 1996-07-16 1999-07-20 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
WO1998026277A2 (fr) 1996-12-12 1998-06-18 Prolume, Ltd. Appareil permettant de detecter et d'identifier des agents infectieux et procede correspondant
AU765703B2 (en) 1998-03-27 2003-09-25 Bruce J. Bryan Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
EP2385069A3 (fr) 2003-11-12 2012-05-30 Biogen Idec MA Inc. Variantes de polypeptides Fc se liant au récepteur (FcRn) néonatal, protéines Fc dimèriques et procédés correspondants
WO2006031370A2 (fr) * 2004-08-19 2006-03-23 Genentech, Inc. Variants de polypeptides dotes d'une fonction effectrice modifiee
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8569460B2 (en) * 2009-03-25 2013-10-29 Vet Therapeutics, Inc. Antibody constant domain regions and uses thereof
CA2754408A1 (fr) * 2009-03-30 2010-10-14 Boehringer Ingelheim International Gmbh Proteines hybrides comprenant des portions fc d'anticorps canins
WO2010117448A2 (fr) 2009-04-05 2010-10-14 Provenance Biopharmaceuticals Corp. Immunocytokines chimériques et leurs procédés d'utilisation
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
US20130129727A1 (en) 2011-11-17 2013-05-23 Nanjingjinsirui Science & Technology Biology Corporation Methods and systems for increasing protein stability
HK1207654A1 (en) * 2012-04-27 2016-02-05 Bioatla, Llc Modified antibody regions and uses thereof
WO2016125495A1 (fr) * 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Anticorps comprenant un domaine se liant à l'antigène dépendant de la concentration d'ions, variants de la région fc, anticorps se liant à l'il-8, et leurs utilisations
CA2980992C (fr) * 2015-04-14 2024-01-23 Akihisa Kaneko Composition pharmaceutique pour la prevention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31
WO2017186928A1 (fr) * 2016-04-29 2017-11-02 Curevac Ag Arn codant pour un anticorps
CN110267674A (zh) * 2016-07-08 2019-09-20 奥美药业有限公司 包含瘦素的融合蛋白及其生产和使用方法
US20200181258A1 (en) * 2016-10-17 2020-06-11 Vetoquinol Sa Modified antibody constant region
CA3071337A1 (fr) 2017-08-15 2019-02-21 Kindred Biosciences, Inc. Variants d'igg fc a usage veterinaire
MX2020009526A (es) 2018-03-12 2020-10-28 Zoetis Services Llc Anticuerpos anti-ngf y metodos de estos.
MX2021002971A (es) * 2018-09-14 2021-05-12 Kindred Biosciences Inc Anticuerpos del receptor anti-interleucina 4 para uso veterinario.
US20210388053A1 (en) 2018-10-18 2021-12-16 Kindred Biosciences, Inc. Fc Variants with Altered Binding to Neonatal Fc Receptor (FCRN) for Veterinary Use
CN113227134A (zh) 2018-12-05 2021-08-06 株式会社梅花治疗 抗体的Fc区变体
MX2021007680A (es) 2018-12-27 2021-10-13 Kindred Biosciences Inc Variantes de igg fc para uso veterinario.
SG11202106478UA (en) 2019-01-03 2021-07-29 Invetx Inc Compositions for increasing half-life of a therapeutic agent in canines and methods of use
US20230348577A1 (en) 2020-02-19 2023-11-02 Adivo Gmbh Modified fc regions
BR112022020944A2 (pt) 2020-04-17 2022-12-27 Zoetis Services Llc Variantes de anticorpos caninos
WO2021212084A1 (fr) 2020-04-17 2021-10-21 Zoetis Services Llc Variants d'anticorps félin
KR20230034954A (ko) 2020-05-11 2023-03-10 인베티엑스 인코포레이티드 개에서 치료제의 반감기를 증가시키기 위한 조성물 및 사용 방법
CN119899259A (zh) 2020-07-10 2025-04-29 因外泰克斯公司 用于延长治疗剂在猫科动物中的半衰期的组合物和使用方法

Also Published As

Publication number Publication date
MX2021008144A (es) 2021-10-13
EP3906259A2 (fr) 2021-11-10
US20200216536A1 (en) 2020-07-09
US11542333B2 (en) 2023-01-03
WO2020142625A2 (fr) 2020-07-09
WO2020142625A4 (fr) 2020-12-10
AU2020205073A1 (en) 2021-08-19
US20240239896A1 (en) 2024-07-18
US20240166748A1 (en) 2024-05-23
SG11202106478UA (en) 2021-07-29
WO2020142625A9 (fr) 2021-06-24
US20230279118A1 (en) 2023-09-07
US20200362035A1 (en) 2020-11-19
US20240166749A1 (en) 2024-05-23
CN113544153B (zh) 2024-12-10
BR112021012513A2 (pt) 2021-09-14
WO2020142625A3 (fr) 2020-10-08
CN120005022A (zh) 2025-05-16
US20240239897A1 (en) 2024-07-18
US11548949B2 (en) 2023-01-10
CN113544153A (zh) 2021-10-22

Similar Documents

Publication Publication Date Title
EP3982932A4 (fr) Compositions et procédés pour véhicules d'administration biologiques
EP3820885A4 (fr) Procédés et compositions pour l'administration d'agents à travers la barrière hémato-encéphalique
EP3874030A4 (fr) Compositions et procédés pour l'ingénierie des lymphocytes t
EP4037695A4 (fr) Compositions oligonucléotidiques et leurs procédés d'utilisation
EP3840730A4 (fr) Compositions pour l'administration d'agents thérapeutiques et leurs méthodes d'utilisation et leurs procédés de préparation
EP3958872A4 (fr) Compositions d'oligonucléotides et leurs procédés d'utilisation
EP3790596A4 (fr) Compositions d'oligonucléotides et leurs procédés d'utilisation
MA51765A (fr) Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
SG11202106478UA (en) Compositions for increasing half-life of a therapeutic agent in canines and methods of use
EP3911338A4 (fr) Compositions et procédés d'inhibition d'antigènes spécifiques de lignée
MA53015A (fr) Anticorps anti-sirp-bêta1 et procédés d'utilisation associés
EP3898942A4 (fr) Compositions de nanoparticules pour l'administration efficace d'acides nucléiques et leurs procédés de fabrication et d'utilisation
MA56455A (fr) Auto-injecteur et procédés d'utilisation associés
EP3774892A4 (fr) Anticorps dirigés contre un composant du complément et procédés d'utilisation
EP3953385A4 (fr) Anticorps cd19 et leurs procédés d'utilisation
EP3917543A4 (fr) Compositions de nitrate améliorées et procédés d'utilisation
EP3877527A4 (fr) Compositions et procédés pour le criblage in vivo d'agents thérapeutiques
EP3826468A4 (fr) Compositions pour l'agriculture et procédés associés
EP3803403A4 (fr) Compositions et procédés d'imagerie
EP3781683A4 (fr) Procédés et compositions pour l'édition génomique
EP3938400A4 (fr) Anticorps cd22 et leurs procédés d'utilisation
EP4048402A4 (fr) Lymphocytes t cytoxiques modifiés et leurs procédés d'utilisation
MA53811A (fr) Anticorps spécifiques à l'apoc3 humaine et du cynomolgus et procédés pour leur utilisation
EP3955738A4 (fr) Compositions et procédés pour moduler l'immunité dans des plantes
MA53167A (fr) Récepteurs chimériques de steap1 et procédés d'utilisation associées